• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对 AML 干细胞抗原 CD96 的亲和力成熟和 Fc 工程化的迷你抗体的增强 ADCC 活性。

Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.

机构信息

Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Zoological Institute, Christian-Albrechts-University, Kiel, Germany.

出版信息

PLoS One. 2012;7(8):e42426. doi: 10.1371/journal.pone.0042426. Epub 2012 Aug 3.

DOI:10.1371/journal.pone.0042426
PMID:22879978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3411760/
Abstract

CD96, a cell surface antigen recently described to be preferentially expressed on acute myeloid leukemia (AML) leukemic stem cells (LSC) may represent an interesting target structure for the development of antibody-based therapeutic approaches. The v-regions from the CD96-specific hybridoma TH-111 were isolated and used to generate a CD96-specific single chain fragment of the variable regions (scFv). An affinity maturated variant resulting in 4-fold enhanced CD96-binding was generated by random mutagenesis and stringent selection using phage display. The affinity maturated scFv CD96-S32F was used to generate bivalent mini-antibodies by genetically fusing an IgG1 wild type Fc region or a variant with enhanced CD16a binding. Antibody dependent cell-mediated cytotoxicity (ADCC) experiments revealed that Fc engineering was essential to trigger significant effector cell-mediated lysis when the wild type scFv was used. The mini-antibody variant generated by fusing the affinity-maturated scFv with the optimized Fc variant demonstrated the highest ADCC activity (2.3-fold enhancement in efficacy). In conclusion, our data provide proof of concept that CD96 could serve as a target structure for effector cell-mediated lysis and demonstrate that both enhancing affinity for CD96 and for CD16a resulted in mini-antibodies with the highest cytolytic potential.

摘要

CD96 是一种新近被描述为在急性髓性白血病 (AML) 白血病干细胞 (LSC) 上优先表达的细胞表面抗原,可能代表着开发基于抗体的治疗方法的一个有趣的靶结构。从 CD96 特异性杂交瘤 TH-111 中分离出 v 区,并用于生成 CD96 特异性可变区单链片段 (scFv)。通过随机诱变和噬菌体展示进行严格选择,生成了亲和力成熟的变体,其 CD96 结合能力增强了 4 倍。亲和力成熟的 scFv CD96-S32F 用于通过基因融合 IgG1 野生型 Fc 区或增强 CD16a 结合的变体来生成二价 mini 抗体。抗体依赖性细胞介导的细胞毒性 (ADCC) 实验表明,当使用野生型 scFv 时,Fc 工程对于触发显著的效应细胞介导的裂解是必不可少的。通过将亲和力成熟的 scFv 与优化的 Fc 变体融合生成的 mini 抗体变体显示出最高的 ADCC 活性(功效提高了 2.3 倍)。总之,我们的数据提供了概念验证,表明 CD96 可以作为效应细胞介导的裂解的靶结构,并表明提高对 CD96 和 CD16a 的亲和力都会导致具有最高细胞毒性潜力的 mini 抗体。

相似文献

1
Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.针对 AML 干细胞抗原 CD96 的亲和力成熟和 Fc 工程化的迷你抗体的增强 ADCC 活性。
PLoS One. 2012;7(8):e42426. doi: 10.1371/journal.pone.0042426. Epub 2012 Aug 3.
2
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.Fc 蛋白和 Fc 糖基工程联合修饰 scFv-Fc 融合蛋白可协同增强 CD16a 结合,但不能进一步增强 NK 细胞介导的 ADCC。
J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.
3
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.通过赋予IgG与FcαRI(CD89)结合能力来增强抗体依赖性细胞介导的细胞毒性。
MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.
4
scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.基于 scFv 的“Grababody”作为一种通用策略,可增强抗体靶向肿瘤的免疫效应细胞募集。
Cancer Res. 2013 Apr 15;73(8):2619-27. doi: 10.1158/0008-5472.CAN-12-3920. Epub 2013 Feb 8.
5
Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.开发一种新型全人源抗 CD123 抗体,以靶向治疗急性髓系白血病。
Leuk Res. 2019 Sep;84:106178. doi: 10.1016/j.leukres.2019.106178. Epub 2019 Jun 27.
6
Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells.新型单链 Fv 抗体片段缀合物针对干细胞抗原 CD123,可有效介导急性髓细胞白血病细胞死亡。
Br J Haematol. 2010 Mar;148(6):879-89. doi: 10.1111/j.1365-2141.2009.08033.x. Epub 2010 Jan 8.
7
Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.通过针对 CD33 和 CD16 的双特异性抗体衍生物有效清除急性髓性白血病细胞。
J Immunother. 2010 Jul-Aug;33(6):599-608. doi: 10.1097/CJI.0b013e3181dda225.
8
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.开发一种具有抗肿瘤活性的新型高亲和力人源抗体,针对实体瘤和血液恶性肿瘤。
FASEB J. 2018 Sep;32(9):5063-5077. doi: 10.1096/fj.201701544R. Epub 2018 Apr 16.
9
Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region.由嵌合小鼠-人IgG亚类和铰链区改变的IgG3抗体诱导的抗体依赖性细胞介导的细胞毒性。
Mol Immunol. 1992 Mar;29(3):319-26. doi: 10.1016/0161-5890(92)90018-s.
10
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.与去岩藻糖基化 Fc 变体相比,新型非对称工程化抗体 Fc 变体具有更高的 FcγR 结合亲和力和特异性。
MAbs. 2013 Mar-Apr;5(2):229-36. doi: 10.4161/mabs.23452. Epub 2013 Feb 13.

引用本文的文献

1
Identification and characterisation of subtype-specific anti-N-CoR OSGEP protease in acute myeloid leukaemia (AML-M5) cell lineage.急性髓系白血病(AML-M5)细胞系中亚型特异性抗N-CoR OSGEP蛋白酶的鉴定与表征
Biotechnol Lett. 2025 Aug 12;47(5):90. doi: 10.1007/s10529-025-03630-3.
2
Flow Cytometric Identification of Hematopoietic and Leukemic Blast Cells for Tailored Clinical Follow-Up of Acute Myeloid Leukemia.流式细胞术鉴定造血和白血病原始细胞,以进行急性髓细胞白血病的个体化临床随访。
Int J Mol Sci. 2022 Sep 11;23(18):10529. doi: 10.3390/ijms231810529.
3
Parallel evaluation of cell‑based phage display panning strategies: Optimized selection and depletion steps result in AML blast‑binding consensus antibodies.

本文引用的文献

1
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.Fc 蛋白和 Fc 糖基工程联合修饰 scFv-Fc 融合蛋白可协同增强 CD16a 结合,但不能进一步增强 NK 细胞介导的 ADCC。
J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.
2
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.基于 TIM3 的差异表达,前瞻性分离正常和白血病干细胞,TIM3 是人急性髓系白血病干细胞标志物。
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5009-14. doi: 10.1073/pnas.1100551108. Epub 2011 Mar 7.
3
平行评估基于细胞的噬菌体展示淘选策略:优化的选择和耗尽步骤导致 AML 原始细胞结合的共识抗体。
Mol Med Rep. 2021 Nov;24(5). doi: 10.3892/mmr.2021.12407. Epub 2021 Sep 7.
4
The characteristics of circRNA as competing endogenous RNA in pathogenesis of acute myeloid leukemia.环状 RNA 作为竞争内源性 RNA 在急性髓系白血病发病机制中的特征。
BMC Cancer. 2021 Mar 15;21(1):277. doi: 10.1186/s12885-021-08029-7.
5
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches.血液系统恶性肿瘤的免疫治疗:新兴疗法和新方法。
Int J Mol Sci. 2020 Oct 27;21(21):8000. doi: 10.3390/ijms21218000.
6
Cluster of Differentiation 96 in Children with Acute Leukemia: A Single Center Cohort Study.急性白血病患儿的分化簇96:一项单中心队列研究
Indian J Hematol Blood Transfus. 2020 Jan;36(1):178-182. doi: 10.1007/s12288-019-01145-2. Epub 2019 Jun 5.
7
Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).靶向白血病干细胞的免疫表型标志物:当前方法的经验教训以及白血病干细胞(LSC)模型的进展如何为急性髓系白血病(AML)的治疗提供更好的策略。
Cold Spring Harb Perspect Med. 2020 Jan 2;10(1):a036251. doi: 10.1101/cshperspect.a036251.
8
Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.用于髓系肿瘤的治疗性抗体——当前进展与未来方向
Front Oncol. 2018 May 18;8:152. doi: 10.3389/fonc.2018.00152. eCollection 2018.
9
Coming of Age: CD96 Emerges as Modulator of Immune Responses.成年期:CD96 作为免疫反应调节剂的出现。
Front Immunol. 2018 May 17;9:1072. doi: 10.3389/fimmu.2018.01072. eCollection 2018.
10
Understanding of leukemic stem cells and their clinical implications.白血病干细胞的认识及其临床意义。
Mol Cancer. 2017 Jan 30;16(1):2. doi: 10.1186/s12943-016-0574-7.
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.
急性髓系白血病中 LMPP 样和 GMP 样白血病干细胞共存。
Cancer Cell. 2011 Jan 18;19(1):138-52. doi: 10.1016/j.ccr.2010.12.012.
4
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.针对人急性髓系白血病干细胞的单克隆抗体治疗。
Oncogene. 2011 Mar 3;30(9):1009-19. doi: 10.1038/onc.2010.511. Epub 2010 Nov 15.
5
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.一种针对 CD123 和 CD33 的重组三特异性单链 Fv 衍生物通过双重靶向介导急性髓系白血病细胞的有效清除。
Br J Haematol. 2010 Sep;150(5):574-86. doi: 10.1111/j.1365-2141.2010.08300.x. Epub 2010 Jul 16.
6
In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.I 型 CD20 抗体的体内细胞毒性严重依赖于 Fc 受体 ITAM 信号传导。
Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-4109. Epub 2010 Mar 30.
7
Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.针对 C 型凝集素样分子-1 的抗体介导免疫疗法治疗急性髓系白血病。
Haematologica. 2010 Jan;95(1):71-8. doi: 10.3324/haematol.2009.009811. Epub 2009 Jul 31.
8
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.CD47是人类急性髓系白血病干细胞的不良预后因素和治疗性抗体靶点。
Cell. 2009 Jul 23;138(2):286-99. doi: 10.1016/j.cell.2009.05.045.
9
RosettaAntibody: antibody variable region homology modeling server.罗塞塔抗体:抗体可变区同源建模服务器。
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W474-9. doi: 10.1093/nar/gkp387. Epub 2009 May 20.
10
CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.靶向CD20的小型模块化免疫药物TRU-015可清除正常和恶性B细胞。
Clin Cancer Res. 2009 Apr 15;15(8):2739-46. doi: 10.1158/1078-0432.CCR-08-1694. Epub 2009 Apr 7.